“Cannabinoids produce analgesia through a variety of mechanisms.
It has been proposed that one mechanism is by modulating the release of CGRP in the spinal cord pain pathways.
Previous studies have reported that cannabinoids, particularly CB2 receptor agonists, can modulate CGRP release in the isolated rat spinal cord.
These results question the role of spinal cord cannabinoid receptors in the regulation of CGRP signalling.”
“This work aimed to investigate the effects of the administration of cannabidiol in a kidney ischemia/reperfusion animal model…
http://www.ncbi.nlm.nih.gov/pubmed/26761477
“In conclusion, the present study suggests that cannabidiol treatment has a protective effect against inflammation and oxidative damage in the utilized kidney ischemia/reperfusion model.” http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-507X2015000400383&lng=en&nrm=iso&tlng=en
“As of September 2015, the cultivation, possession, and/or use of marijuana is illegal under U.S. federal law as a Schedule I narcotic; however, it is legal in four states and Washington, D.C. Forty-six states allow some form of medicinal marijuana or decriminalization.
Marijuana has been used medicinally for thousands of years; Marijuana’s regulation by law enforcement in the U.S., rather than the medical community, led to an almost complete halt to academic and scientific research after the 1930s.
The late 1960s saw an upsurge in recreational marijuana use by middle-class youth, the majority of whom experienced minimal adverse effects aside from arrest and attendant legal complications.
Since the mid-1990s, the use of medicinal marijuana for certain conditions has gained increasing acceptance.
In the East, the feeling is primarily that marijuana continue to be proscribed. In the West, where clinicians must face the realities of medicalization, decriminalization, and/or legalization, as well as widespread recreational use, there is more of a movement to minimize adverse effects, particularly on youth.”
“JWH-015, a cannabinoid receptor 2 (CB2) agonist has tumor regressive property in various cancer types.
These data confer the impact of this cannabinoid on anti-proliferative and anti-tumorigenic effects, thus enhancing our understanding of its therapeutic efficacy in NSCLC.
Our findings open new avenues for cannabinoid receptor CB2 agonist-JWH-015 as a novel and potential therapeutic target based on EGFR downregulation mechanisms in NSCLC.”
“Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required.
This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales.
The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included.
Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity”
http://www.ncbi.nlm.nih.gov/pubmed/26750641
http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/
“Although marijuana is principally used as a psychoactive substance, it has also been used for medical and religious purposes for over 2000 years.
This review concluded that there was evidence of a positive and moderate short-term trend toward a reduction of pain.
There are a number of reasons why naturally occurring cannabis or cannabinoid drugs might have a pharmacologic effect on headache..
It has been suggested that one explanation for migraine and other headache disorders may be an underlying endocannabinoid deficiency.
…cluster headache attacks were relieved within 5 minutes by the inhalation of marijuana.
Subsequent treatment with dronabinol (THC) 5 mg orally also provided the patient relief within 15 minutes.”
http://www.medscape.com/viewarticle/738529_2
http://www.thctotalhealthcare.com/category/headachemigraine/
“One hundred percent of migraine sufferers in a self-report survey said cannabis reduced migraine pain and discomfort.”
“Cannabis treats a wide variety of conditions, but specific formulations are better for some symptoms than others, patients report in a new landmark survey by a medical cannabis industry company Care By Design.
A full 100 percent of respondents with headaches, migraines, fibromyalgia, irritable bowel syndrome (IBS), and spinal cord injury reported a decrease in pain or discomfort on medical marijuana rich in the molecule cannabidiol (CBD).”
http://blog.sfgate.com/smellthetruth/2015/09/15/survey-medical-pot-treats-migraines/
http://www.thctotalhealthcare.com/category/headachemigraine/
“Our brain’s own endogenous marijuana-like chemicals produce analgesia by modulating the entry of pain signals into the brain at the level of our spinal cord.
Future generations of pain relievers will likely be developed based upon the action of marijuana in the body.
The advantage of targeting the endogenous marijuana system is that only noxious or painful signals are blocked; normal touch sensation is normal.
This study may lead to the development of more effective migraine prevention and treatment.
The challenge will be to find a dose of marijuana that produces pain relief without disturbing normal cognitive function.”
https://www.psychologytoday.com/blog/your-brain-food/201309/marijuana-migraines
http://www.thctotalhealthcare.com/category/headachemigraine/
“No clinical trials are currently available that demonstrate the effects of marijuana on patients with migraine headache; however, the potential effects of cannabinoids on serotonin in the central nervous system indicate that marijuana may be a therapeutic alternative.
Thus, the objective of this study was to describe the effects of medical marijuana on the monthly frequency of migraine headache.
The frequency of migraine headache was decreased with medical marijuana use.
Prospective studies should be conducted to explore a cause-and-effect relationship and the use of different strains, formulations, and doses of marijuana to better understand the effects of medical marijuana on migraine headache treatment and prophylaxis.”
http://www.ncbi.nlm.nih.gov/pubmed/26749285
http://www.thctotalhealthcare.com/category/headachemigraine/
“We investigated associations between adolescent cannabis use and IQ and educational attainment in a sample of 2235 teenagers from the Avon Longitudinal Study of Parents and Children.
After full adjustment, those who had used cannabis ⩾50 times did not differ from never-users on either IQ or educational performance.
Adjusting for group differences in cigarette smoking dramatically attenuated the associations between cannabis use and both outcomes, and further analyses demonstrated robust associations between cigarette use and educational outcomes, even with cannabis users excluded.
These findings suggest that adolescent cannabis use is not associated with IQ or educational performance once adjustment is made for potential confounds, in particular adolescent cigarette use.
Modest cannabis use in teenagers may have less cognitive impact than epidemiological surveys of older cohorts have previously suggested.”